Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 3/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 7/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765605 | 0.83 | HDAC1 (0.39) | NTRK1CASP1ELANEMETKCNQ3 | |
| SCHEMBL30765582 | 0.78 | KDM4C (0.42) | NTRK1NTRK3MTNR1B | |
| SCHEMBL30765506 | 0.78 | NTRK1 (0.51) | NTRK1NTRK3 | |
| SCHEMBL30765928 | 0.77 | DGAT2 (0.44) | NTRK1CASP1NTRK3ELANEMTNR1B | |
| SCHEMBL30765788 | 0.74 | NTRK1 (0.38) | NTRK1 | |
| SCHEMBL30765974 | 0.73 | CASP1 (0.44) | NTRK1CASP1NTRK3ELANE | |
| SCHEMBL30765852 | 0.70 | NTRK1 (0.38) | NTRK1NTRK3 | |
| SCHEMBL30765718 | 0.70 | NTRK1 (0.45) | NTRK1NTRK3MTNR1B | |
| SCHEMBL31558568 | 0.69 | NTRK1 (0.45) | NTRK1CASP1NTRK3ELANE | |
| SCHEMBL27144443 | 0.68 | MAPK14 (0.34) | MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |